Could a common supplement help fatty liver disease?

NCT ID NCT04669158

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and scarring. Participants received either idebenone or a placebo for a set period, and researchers monitored side effects and changes in liver health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis fibrotic liver disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIBROSIS NON-ALCOHOLIC STEATOHEPATITIS

Contacts and locations

Locations

Digestive Health Center, Stanford University

Redwood City, California, 94063, United States
Stanford University

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.